Cargando…
Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma
Small molecular inhibitors targeting BRD4 family proteins are emerging as promising therapies in many types of human malignancies. However, whether BRD4, as well as other BET family members, may serve as therapeutic targets in renal cell carcinoma (RCC) remains unknown. In this study, we found that...
Autores principales: | Chen, Wei, Zhang, Hao, Chen, Zhifeng, Jiang, Hao, Liao, Liping, Fan, Shijie, Xing, Jing, Xie, Yiqian, Chen, Shijie, Ding, Hong, Chen, Kaixian, Jiang, Hualiang, Luo, Cheng, Zheng, Mingyue, Yao, Zhiyi, Huang, Yiran, Zhang, Yuanyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212493/ https://www.ncbi.nlm.nih.gov/pubmed/30385738 http://dx.doi.org/10.1038/s41389-018-0093-z |
Ejemplares similares
-
PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma
por: Wang, Jianfeng, et al.
Publicado: (2021) -
17-AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA-MB-231 breast cancer cells
por: Zuo, Yu, et al.
Publicado: (2020) -
A Genetic Algorithm Based Support Vector Machine Model for Blood-Brain Barrier Penetration Prediction
por: Zhang, Daqing, et al.
Publicado: (2015) -
Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing
por: ZHANG, QI, et al.
Publicado: (2016) -
L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression
por: Huang, Jing, et al.
Publicado: (2022)